Diagnostic Limitations of Magnifying Endoscopy with Narrow-band Imaging in Early Gastric Cancer
Overview
Authors
Affiliations
Magnifying endoscopy with narrow band imaging (M-NBI) has made a huge contribution to endoscopic diagnosis of early gastric cancer (EGC). However, we sometimes encountered false-negative cases with M-NBI diagnosis (i. e., M-NBI diagnostic limitation lesion: M-NBI-DLL). However, clinicopathological features of M-NBI-DLLs have not been well elucidated. We aimed to clarify the clinicopathological features and histological reasons of M-NBI-DLLs. In this single-center retrospective study, M-NBI-DLLs were extracted from 456 EGCs resected endoscopically at our hospital. We defined histological types of M-NBI-DLLs and analyzed clinicopathologically to clarify histological reasons of M-NBI-DLLs. Of 456 EGCs, 48 lesions (10.5 %) of M-NBI-DLLs were enrolled. M-NBI-DLLs was classified into four histological types as follows: gastric adenocarcinoma of fundic-gland type (GA-FG, n = 25), gastric adenocarcinoma of fundic-gland mucosal type (GA-FGM, n = 1), differentiated adenocarcinoma (n = 14), and undifferentiated adenocarcinoma (n = 8). Thirty-nine lesions of M-NBI-DLLs were -negative gastric cancers (39/47, 82.9 %). Histological reasons for M-NBI-DLLs were as follows: 1) completely covered with non-neoplastic mucosa (25/25 GA-FG, 8/8 undifferentiated adenocarcinoma); 2) well-differentiated adenocarcinoma with low-grade atypia (1/1 GA-FGM, 14/14 differentiated adenocarcinoma); 3) similarity of surface structure (10/14 differentiated adenocarcinoma); and 4) partially covered and/or mixed with a non-neoplastic mucosa (1/1 GA-FGM, 6/14 differentiated adenocarcinoma). Diagnostic limitations of M-NBI depend on four distinct histological characteristics. For accurate diagnosis of M-NBI-DLLs, it may be necessary to fully understand endoscopic features of these lesions using white light imaging and M-NBI based on these histological characteristics and to take a precise biopsy.
Ligato I, De Magistris G, Dilaghi E, Cozza G, Ciardiello A, Panzuto F Diagnostics (Basel). 2024; 14(13).
PMID: 39001267 PMC: 11241412. DOI: 10.3390/diagnostics14131376.
Global progress and future prospects of early gastric cancer screening.
Huang Y, Shao Y, Yu X, Chen C, Guo J, Ye G J Cancer. 2024; 15(10):3045-3064.
PMID: 38706913 PMC: 11064266. DOI: 10.7150/jca.95311.
Ueyama H, Hirasawa T, Yano T, Doyama H, Isomoto H, Yagi K DEN Open. 2024; 4(1):e359.
PMID: 38601269 PMC: 11004903. DOI: 10.1002/deo2.359.
Fu Y, Zhang S, Ma L, Zhao Z, Liao H, Xie T Biomed Opt Express. 2024; 15(2):506-523.
PMID: 38404328 PMC: 10890891. DOI: 10.1364/BOE.506134.
Gastric adenocarcinoma of the fundic gland type: A review of the literature.
Zhai Z, Hu W, Huang Z, Chen Z, Lu S, Gong W JGH Open. 2024; 7(12):812-825.
PMID: 38162862 PMC: 10757499. DOI: 10.1002/jgh3.13014.